Sometimes, career moves happen purely by chance. Just ask Adam Chernick, PhD/MBA, an associate at IDT (a Danaher business), who was in the right place at the right time for a tremendous career opportunity.
In 2016, while working on his PhD, Adam was considering using an IDT product to selectively enrich a specific viral genome to improve the on-target sequencing rate. He was working with IDT’s applications support team to explore that solution and had a discussion with the local sales manager, who mentioned he was looking to hire an inside sales representative.
“I’d already been considering non-academic careers at that point, and the opportunity to move into a non-academic career while still getting to use my scientific knowledge every day was very compelling—and IDT sounded like the kind of place where I could do that,” explained Adam. “It was also an opportunity to learn more about the business side of science, where I really had no personal experience.”
Adam was hired for that role and two years later, IDT was acquired by Danaher. Every few years, he progressed to higher roles until landing in his current role as Senior Commercial Product Manager – CRISPR, in May 2023.
Today, he manages a team of Commercial Product Managers who oversee the launch and maintenance of IDT’s CRISPR and Functional Genomics products. He works closely with other teams to take mature technologies and get them ready for customers to purchase and use in their own experiments. He also collaborates with many other IDT functional teams—from manufacturing and R&D to legal and sales—on product updates such as new features, pricing and marketing materials.
Thriving in a culture of continuous improvement
With access to Danaher’s portfolio of best practices (known as the Danaher Business System or DBS), Adam finds his work especially fulfilling.
“DBS helps us tackle a whole range of business and technical challenges in reproducible and dependable ways,” he said. “Danaher has been using DBS successfully for decades, and the DBS toolbox has taken that success and enshrined it into something everyone here can use in their daily work.”
Making a real difference—one experiment at a time
“It’s exciting to see my work contribute to something that scientists all around the world use every day,” he said. “Not every industry gets to say that they contribute to positive change in the world, but IDT products are integral for customers who are advancing medicine and our collective understanding of biology—that’s truly inspiring.”
“While customers are doing their work, we’re committed to learning about their challenges and developing tools to help overcome them,” he added. “This is a really satisfying way to apply my technical background to solving problems that’s a little different from running my own research program in an academic setting.”
Going forward, Adam isn’t sure what his career future looks like, but he knows it will be exciting.
“Most of the products I support are based on CRISPR, a technology that’s barely a decade old,” he said. “I doubt anyone can truly predict what the future holds in such an innovative and dynamic industry, but I’m excited to be part of it.”
Imagine you’re just starting your career. You take a position at a company that’s new to you, thinking you’ll be there for a year or two.
Fast forward two decades: You’re at the same parent company—or maybe you’ve gone somewhere else great—and taken on several different roles, including leadership positions. You’ve had inspiring mentors, and you’ve been a mentor to others, across many industries and geographies. You’ve received the structure, focus, and support you need to not only achieve your goals but far exceed what you originally envisioned for yourself.
These possibilities are all realities at Danaher. Due to Danaher’s unique ecosystem, there’s always an opportunity to develop new skills, transition into a new role, and take on leadership.
Danaher is our corporate parent company, providing vision, strategy, and support to our people worldwide. We’re comprised of three platforms: Life Sciences, Diagnostics, and Biotechnology.
Life Sciences: We enable cutting-edge R&D for leading Life Science companies worldwide, accelerating innovation that helps people lead longer, healthier lives. We have a proud record of partnering with academic, clinical and government scientists, applying our scientific and operational expertise to help them understand diseases and infections, pioneer more effective treatments and develop more efficient workflows. Across the Life Sciences, we work collaboratively to drive advancements towards real-life impact.
Diagnostics: We enhance the effectiveness of diagnostics wherever healthcare occurs. Our Diagnostics businesses tailor proven methodology, advanced tools and integrated solutions to solve our customers’ most pressing challenges. We focus on quality, productivity, automation and scale, with a global reach that ensures we can deliver superior diagnostic capabilities wherever and whenever they are needed.
Biotechnology: Our Biotechnology segment brings together dedicated technical expertise and talent to help our customers commercialize the next generation of therapeutics. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotechnology, large-scale biopharmaceutical, and contract manufacturers.
Our platforms share critical missions and expertise, and together they enable Danaher’s global reach and power to help save lives. Across the platforms are more than 15 independent businesses. Each has its own leadership, culture, associates, and bottom line, and all are driven by the larger purpose of helping realize life’s potential.
What does the Danaher family, as we sometimes call it, mean for you? In a word: opportunity. When you join us, you’ll become part of a proven global corporation and have the chance to make an impact at your OpCo. And because we’re united by the same set of resources, tools and processes—with the Danaher Business System as our foundation—you can move between OpCos to grow your career or collaborate with your counterparts across OpCos. Whatever your career goals, you can achieve them within Danaher.
Want to build your career at a company with limitless opportunities? Search our open jobs and join our talent community to take the first step!
At Danaher, we are committed to advancing precision medicine through innovative diagnostic solutions and enabling healthcare providers to diagnose disease with unprecedented speed and accuracy. We foster innovation through collaboration across our businesses and cutting-edge technologies.
Hear from some of our top associates on why they love working at Danaher’s diagnostics companies and about the impact of their work on patient outcomes around the world.
Over the past decade, CRISPR has taken life sciences and the biomedical world by storm for its ability to easily and precisely edit DNA. Today at Integrated DNA Technologies (IDT) (a Danaher company), Bahri Karacay, PhD, Sr. Manager, Product Marketing Gene Writing and Editing, applies himself to advancing this innovative technology, both for research and therapeutic applications. Not only is this work his passion, it’s also his way of helping Danaher innovate at the speed of life.
Dr. Karacay at IDT’s Therapeutic Oligonucleotide Manufacturing facility.
Tell us a bit about your background.
Originally from Türkiye, I came to the US for graduate school. I received my PhD from The Ohio State University and did part of my postdoctoral work at Nationwide Children’s Research Institute in Columbus. After my lab moved, I completed my postdoctoral work at the University of Iowa, Carver College of Medicine. I continued after finishing my postdoc as a research scientist in its Child Neurology Division.
What drew you to IDT initially?
As a research professor at the University of Iowa, Carver College of Medicine and a long-standing customer of IDT, I knew IDT and its solutions very well. I was always curious about working in the life sciences industry, so when I was ready to make the switch from academia to industry, IDT was the first logical place to start.
What does your current role entail?
Currently, I lead a product marketing team for the Gene Writing and Editing product portfolio. That includes CRISPR genome editing products and services, both for research and therapeutic applications, as well as gene regulation and synthetic biology products that are mainly for research applications. In simplest terms, we empower scientists to rewrite the code of life through strategic marketing, data-driven insights, and engaging educational content.
What does your day-to-day work look like?
My day-to-day work is dynamic, revolving around strategy, collaboration and execution. I develop marketing strategies and tactics to drive the success of our portfolio, focusing on customer-centric messaging and market trends. Leading a talented team, I provide guidance and support on various projects. Additionally, I serve on cross-functional teams to bring innovative products and services to market.
Since last year, I’ve also enjoyed supporting cross-company initiatives between IDT and Aldevron, another Danaher business. Together, we work towards delivering impactful solutions for customers in the cell and gene therapy space, including Current Good Manufacturing Practice (CGMP) manufacturing and Research Use Only (RUO)-to-CGMP workflows. My work is a blend of strategic thinking, creativity, science, and teamwork—making every day exciting and fulfilling.
Dr. Karacay at the University of Iowa
Since you’ve been with IDT, what are some of your most memorable moments?
One of the most memorable moments was the ribbon-cutting ceremony for IDT’s state-of-the-art therapeutic oligonucleotide manufacturing (TOM) facility in October 2023. This marked a major milestone for IDT, as it represented our entry into therapeutic space. Until then, we had primarily supported our customers in the discovery phase of their research. With the opening of the TOM facility, we now offer a comprehensive end-to-end workflow solution—from bench to bedside.
This achievement was particularly meaningful to me as a former scientist with firsthand experience in gene therapy. I had conducted research focused on developing therapies for two devastating conditions: neuroblastoma, a pediatric cancer of the nervous system typically diagnosed before age five, and Alexander Disease, a rare and fatal neurodegenerative disorder that most commonly strikes in the first decade of life.
Why are you inspired and excited by CRISPR technology?
CRISPR technology has already revolutionized scientific research, and its impact is now transforming medicine as well. With the first CRISPR-based therapies having been approved in December 2024 both in Europe and the United States, we are witnessing the rapid evolution of the technology from research tool to life-saving treatment modality. From groundbreaking cancer treatments to innovative therapies for genetic diseases, CRISPR’s potential seems limitless.
How is your career as a part of Danaher accelerating the power of science and technology to improve human health?
Though I am no longer directly involved in gene therapy research, I feel as though I am still walking side by side with the scientists who are striving for the same life-changing goals. Developing gene therapies for diseases was my passion and purpose, and now, with CRISPR genome editing making that dream a reality, I am proud to continue contributing by enabling scientists with IDT products and resources.
What are some of your interests outside of work?
I’m the founder and lead singer of TURKANA, a band comprised of Turkish and American musicians performing Turkish folk and pop music. I’m also a popular science writer, podcaster and the author of two bestsellers: “The Secret of Life DNA” and “Happy Brain”. My favorite pastime activities are making music and skiing.
Dr. Karacay’s band TURKANA is comprised of professors from the University of Iowa Carver College of Medicine. They play Turkish pop and folk tunes, as well as some of Dr. Karacay’s original compositions, at festivals, concerts, cultural events and radio programs.
Why do you think other people in your field would enjoy a job at IDT or another Danaher company?
IDT and other Danaher life sciences companies are great places to work for anyone passionate about advancing science and human health. With Danaher’s promise of ‘innovation at the speed of life’ and IDT’s focus on ‘Accelerating the pace of genomics,’ we’re committed to pushing the boundaries of what’s possible.
Initiatives like the IGI Beacon Program, which aims to expand access to CRISPR technologies, and partnerships that improve genome-editing precision, highlight our impact on global challenges. Associates at IDT or other Danaher life sciences companies benefit from cutting-edge tools, a collaborative culture, and opportunities to grow professionally, making it an ideal environment for those driven to shape the future of science and health. I’ve seen the work we do here and it’s incredibly rewarding to be part of it.
The secret to a thriving career is having access to the right opportunities. At any one time, Danaher has more than 1,400 open roles across multiple high-impact industries, with more than 15 businesses on six continents. Based on her own experience, Marcy Engelstein, VP of Marketing at Pall (a Danaher company), is a strong believer that Danaher is the place to find those opportunities.
During a recent discussion, Marcy shared how joining Danaher was a catalyst for her success.
What is your career background and how did you first come to Danaher?
I spent my first 10-12 years in academic research mostly around genetics and genomics topics. I worked at Harvard, MIT, and Mass General Hospital. I’m most proud of the fact that I was part of the global team that helped sequence the Human Genome in the 90s.
From there, I moved into an R&D leader role at Millipore Corporation (a competitor to Pall Life Sciences). I was there for 15 years, in various roles across R&D, project management and marketing before joining Beckman Coulter (a Danaher company) in 2014 as a Global Senior Marketing Manager for the DNA sequencing services business.
Tell us about your Danaher career evolution. What moves did you make between Danaher operating companies?
I have been with Danaher since 2014. I started at Beckman Coulter and then took a role at Danaher Diagnostics, then at Leica Biosystems, and finally at Pall, where I am today.
My first internal move came about in an interesting way. I met with a colleague who was starting up an innovation team at Danaher. Her team’s goal was to look at the impact of new technologies and market shifts over a longer horizon (about five to 20 years), to identify opportunities or threats to our business and help Danaher companies prepare for what may come in the future.
Her team’s objective was very intriguing to me, so much so that I suggested she would need to add marketing muscle to her very technology-heavy team, and when she was ready, she should reach out to me. That actually happened about a year later. I was in that Danaher role around three years and really enjoyed it; but I missed having a more near-term impact. With that in mind, I set my sights on returning to a marketing role with product and sales support responsibility. While facilitating a DBS (Danaher Business Systems) course, I met an associate who connected me to a role in Leica Biosystems (another Danaher company) as Marketing Director for Staining Reagents.
What prompted your move from Leica Biosystems to Pall?
While I was at Leica overseeing marketing for staining reagents, Pall reached out to me via Danaher Go (a program that helps Danaher hire from within). Pall’s Aerospace business unit was seeking its next head of Marketing. At first, I was skeptical since the Aerospace market was very unfamiliar to me. My career had been centered on life science and diagnostics businesses. What convinced me to join was the challenge and opportunity of the role, the passion and collaborative nature of the associates I met through the interview process and the comfort of knowing I was already familiar with the DBS tools and business processes I would need to excel. Plus, having been at a Pall competitor for so many years, I felt my knowledge in the filtration space would support my transition.
Marcy and family at their annual beach vacation.Marcy and her family on vacation exploring Hawaii in 2021.
How does Danaher make finding a new role easier?
Danaher offers the Danaher Go program which encourages associates to explore roles across Danaher confidentially. Through the program, associates can explore potential new roles and it has given me the confidence to explore new opportunities that stretch my skills. This, along with networking with other associates while facilitating Kaizens, helped me move between different roles at Beckman, but also helped in my move from Beckman to Leica Biosystems and then to Pall.
What’s next for you?
With upcoming retirement, and soon-to-be empty nesting, my husband and I plan to relocate from Massachusetts to the Colorado mountains. I have come to love hiking, skiing, biking—anything outdoors—which were not activities I participated in growing up. Our intent is to be outdoors every day, doing some fun and active endeavors.
Rob Monroe joined Danaher over two years ago as Chief Scientific Officer (CSO) in oncology and Chief Medical Officer for Leica Biosystems. Throughout his time with Danaher, he has worked with leadership and other teams to innovate oncology diagnostics. Hear his experience with Danaher in his own words.
Briefly introduce yourself and how long you’ve worked with Danaher. Tell us about your role.
I’ve been with Danaher for two and a half years. I’m a pathologist by training. I’m MD and PhD trained, and then I did residency training and pathology and worked in the clinical world as a practicing pathologist for a few years before I moving into industry work.
I joined Danaher with a dual role as CSO for oncology for the diagnostics platform and medical officer for Leica Biosystems.
What prompted you to make the leap from a clinical role to industry?
I really wanted to be involved in something more innovative and science-focused beyond the straight practice of pathology. That really spurred me to look into areas of industry where my training could be valuable to the types of products and innovations that were being developed in the diagnostics industry.
Can you share any standout parts of the work that you’ve done in the last two and a half years? Any projects you have been a part of that you’re really proud of?
It’s been really exciting to work with leadership in different areas of the company and share my vision for becoming more innovative. I’ve had the opportunity to set up some really exciting collaborations.
For example, with Yale University and one of our scientific advisory board members, we set up a Beacon project to develop a test for an exciting new therapy for breast cancer patients. So that’s one that I’m really excited about.
What do you think the future holds for your career? What are you looking forward to in the industry?
What I’m really excited about is building capabilities within Danaher that don’t exist now, which can help us to really advance and accelerate the development of really impactful diagnostics. I’d love to see these tests coming through and making an impact on patients’ lives.
Is there anything else you want to share with future candidates about working with Danaher?
One area is the way that Danaher goes about doing things. It’s extremely valuable not just for people who are business oriented, but people who want to apply and learn how to run groups and how to develop products. I think the Danaher Business System is a great part of the experience of Danaher that really adds to the culture and the richness of the experience here.
Advance Life-Saving Research
Whether you work in oncology diagnostics at Leica Biosystems or serve in one of Danaher’s 15+ businesses, you have the chance to do work that impacts the lives of millions of people globally. A career at Danaher means collaborating with dedicated and caring experts to unlock the future of science and technology.
When Ephraim Tsalik transitioned from academia to Danaher, he had the chance to combine his infectious disease expertise with teams across various Danaher operating companies. His work aims to accelerate medical product advancement and improve the future. We met Ephraim to discuss his experience and future goals.
Tell us about your role and what your day-to-day looks like.
My role is chief scientific officer for infectious diseases for Danaher Diagnostics.
Before joining Danaher, I was in academia. I was a tenured associate professor at Duke University, and now I maintain an adjunct appointment there. I’m an infectious disease physician by training, and I still do clinical work at the Veteran’s Affairs (VA) hospital in Durham, North Carolina.
In my role at the platform, I have the privilege of getting to interface with a lot of different stakeholders that are both internal and external to figure out what opportunities we should be pursuing.
Do you like the work that you’re doing?
I love it. It’s a lot of fun.
I came in part because I have something to give, but I also have a tremendous amount to receive just working with people who are thinking about the marketing components, the technical components, the commercial elements, and just having all of those different perspectives come together so that we can ultimately advance a product that does good in the world, but also is sort of constrained by the realities of how you make something that people are actually going to use and buy.
What are you looking forward to in your career at Danaher?
One of the things that seems to be shifting to some extent at Danaher is that there’s a recognition that if we’re only focused on the next few years, we’re going to miss out on the activities that we need to start now in order to really innovate and drive the field forward five years from now, seven years from now, 10 years from now.
Given that recognition, there are mechanisms to help enable some of that earlier-stage research, like the Beacon programs, which are opportunities to engage with external collaborators — typically in academia — to help cultivate some of the research that they’re doing with an eye on bringing those discoveries internally to Danaher to develop the products of the future.
Is there anything else that you would like to share for future candidates?
One thing that I wanted to mention for people who may be looking at a similar transition from academia or the clinical world into industry: Danaher is a place that very much embraces the idea of maintaining that visibility. In Danaher speak, going to Gemba, going to where things are, where the things are happening — I found that really valuable to maintain that connection so that I could continue to be a voice of the customer for the company.
Accelerate the Future of Science and Technology
A career at Danaher means working with leading experts across science and technology. Combine your unique expertise with the power of a global organization to create a meaningful impact for people everywhere.
At Radiometer, part of the Danaher family, leadership is all about driving continuous improvement and empowering our teams to shine. We sat down with Tiffany Murphy, our US Commercial General Manager, to hear about her unique management style, how the Danaher Business System (DBS) supports her work, the exciting changes she’s led, and how Danaher has invested in her journey.
Photo: Tiffany Murphy and her family
Adapting Leadership to Empower Teams
“I flex my leadership style based on the associate’s needs or situation. However, the style I align closest to is the ‘transformational leader’ – focused on continuous improvement and empowering the team to be problem-solvers. As a leader, I think it’s imperative to go to gemba or “where the work happens” to deeply understand the state of the business, the customer experience, or the challenges that my organization is facing. Then, I ruthlessly prioritize the most critical areas of opportunity!”
Tiffany believes in being flexible and adaptable, tailoring her leadership to meet the unique needs of her team and the challenges at hand. By embracing a transformational leadership style, she creates an environment where everyone feels empowered to innovate and tackle problems head-on.
Leveraging the Danaher Business System for Excellence
“Danaher, and thus Radiometer, is built on the foundation of the Danaher Business System (DBS). It is the ‘how’ we do our work. When we apply the principles of DBS, we expand our capabilities, improve our processes, execute at a higher level, and sustain performance. This ultimately gives us a unique competitive advantage.”
DBS is at the heart of Radiometer’s operations. By consistently applying DBS principles, the team enhances processes, drives continuous improvement, and maintains high performance, giving Radiometer a unique edge in the healthcare industry.
Driving Growth and Enhancing Experiences
“We are driving significant growth through improving our commercial rigor and execution, expanding our teams, and working on improving our overall customer AND associate experience. “Under Tiffany’s leadership, Radiometer America focuses on robust growth by strengthening commercial strategies, growing the team, and enhancing customer and associate experiences. These initiatives ensure that Radiometer continues to meet the evolving needs of the healthcare sector while providing a supportive and dynamic workplace.
A Journey of Professional Growth within Danaher
“I have essentially grown up at Danaher and will celebrate my 25th year soon. I have progressed my career through experience at three different Danaher Operating Companies. I have been afforded the opportunity to attend many leadership development programs, received valuable coaching from many great leaders and mentors, and gained my MBA with the tuition assistance program. My family has been blessed by the opportunities I have gained here.”
Tiffany’s 25-year journey with Danaher highlights the company’s commitment to nurturing talent. Through many experiences, leadership training, and educational support, Danaher has played a crucial role in her personal and professional growth, enabling her to lead Radiometer with expertise and passion.
We spoke with Martin Stumpe, PhD, Danaher’s newly appointed Chief Data and AI Officer, about the future of AI in healthcare and life sciences.
Martin Stumpe has built a career around imagining and building new technology to solve complex human problems. He’s served as the Chief of AI at precision medicine company Tempus, founded and led Google’s Cancer Pathology project, contributed exoplanet-detecting algorithms to NASA’s Kepler mission, and worked at Stanford University on protein folding simulations.
Now, Martin is stepping into his latest role as the Chief Data & Artificial Intelligence Officer at Danaher, where he leads the company’s AI strategy, capability development and execution. We spoke with Martin about his first several months at Danaher, his vision for what AI can do to power the future of healthcare and life sciences, and how he plans to turn those visions into reality.
What compelled you to join the Danaher team?
Simply put: the opportunity for immense impact on healthcare. My background is as a technologist but I have always been interested in healthcare and life sciences. Perhaps nowhere else is there such tremendous potential for good data, well used, to make our systems run smarter and to make us all healthier. Danaher’s exceptional portfolio of companies across diagnostics, life sciences and bioprocessing is an immense platform for positive impact on human health and lives. We have the devices, the global install base and the assays, plus the world-class operational excellence, to make one of the most meaningful plays in the healthcare space when powered by the right technology. I couldn’t resist the opportunity to make that vision real.
What are the unique challenges in applying AI to healthcare and life science?
AI cannot solve problems in a vacuum. In order to develop AI and impact in the real world, many factors need to be considered. This includes creating the right data that is of the quality and quantity to be fit-for-purpose for AI. Similarly, the outputs of AI need to be integrated back into the real world, via thoughtful integration into workflows, products, and human processes. In healthcare and life sciences, additional challenges such as regulatory processes, reimbursement, and legacy systems have to be overcome. Consequently, there are a lot of medical AI algorithms out there that aren’t getting used, and a lot of datasets that aren’t being leveraged. We are starting with the end in mind and take a holistic approach to building and leveraging AI towards real impact. This also includes building the organizational readiness and change management infrastructures to make end-to-end integration feasible.
Where do you see the greatest promise for building out Danaher’s AI capabilities?
There are several areas where we are working on using AI to improve productivity or products across Danaher. To name a few representative examples that we are quite focused on at the moment:
Danaher has a large portfolio of imaging instruments across life sciences and diagnostics. With modern computer vision and multimodal AI, we have the opportunity to increase the insights users of our instruments are getting from these devices. This includes more accurate image analysis, and contextualization of image data with non-imaging modalities to, as one example, achieve a multimodal understanding of the spatial and molecular features of the tumor microenvironment. This can lead to actionable insights for the development or application of immunotherapy in various cancers. In the life sciences, similar insights can help to shed light onto drug mechanisms of action for further improvement.
Another area where we see tremendous potential is leveraging in silico approaches to design and optimize molecules, such as ligands with higher affinity in chromatography or more stable mRNA, or antibodies with specific properties in diagnostic applications. This is also an area where the integration between AI and the wet lab validation in the real world needs to be well designed, in order to facilitate a tight feedback cycle for rapid iteration. Ultimately this will help reduce the time to market and cost of designing new drugs – especially advanced therapies – and set the stage for automated yet personalized drug development.
Last but certainly not least is how Danaher uses AI to run more smoothly as an organization. We already see many examples of how AI can increase productivity in our everyday lives – such as information retrieval and synthesis, data analysis, or content creation. We see a lot of opportunities across Danaher to bring similar powerful tools into workflows across many areas to assist our associates with various administrative tasks. Not surprisingly, having high-quality and connected data is a key requirement to unlock the true potential, so we are investing into this area to maximize the impact we will achieve.
What are the biggest risks your work faces?
Truly transformative technologies solve entire problem classes for humanity. The internet “solved” information access. Cell phones “solved” communication. AI has that same potential in healthcare and life sciences – but we need to think at just the right scale. If we choose only small problems to solve, we will achieve only incremental change. If we think too big, we risk getting lost in an infinite number of opportunities – some of which might even be solutions to problems that don’t really exist or have meaningful impact on people’s lives. So we need to be incredibly thoughtful about how we set boundaries on the problems we solve. Think big, but track progress along the way and adjust where necessary.
What’s your first step?
My first focus is our people power. This means building up our talent pool, both by nurturing internal talent and looking beyond our walls for people to bring in as employees and collaborators. We already have a robust program of collaboration through our Beacons program, which continues to be a fruitful source of brilliant ideas. There are other areas where we are making significant investments in building out our AI capabilities, including in data and in infrastructure for AI. And I’m looking forward to our Danaher Summit – this year focused on AI’s role in predictive R&D – and its ability to gather experts across the entire ecosystem, from academia through industry and beyond.
What inspires you most about being at Danaher?
I have been consistently impressed by the people at Danaher. The culture here emphasizes continuous growth, humility, and mission-driven teamwork, which is a crucial foundation for the challenging and important work we have ahead of us. I am enthusiastic about driving real impact with this fantastic team.
At Radiometer, leadership is about more than just managing teams—it’s about making a meaningful impact on our associates and the customers we serve. Eduardo Marin, Regional Director of Human Resources for the Americas, embodies this philosophy through his dedication and personal experiences. Here’s a glimpse into Eduardo’s inspiring journey and the larger impact Radiometer is making in the healthcare industry.
A Personal Connection to Radiometer’s Mission
“My name is Eduardo Marin, and I’m the Regional Director of Human Resources for the Americas Region at Radiometer. I take great pride in my work, as it allows me to make a difference in the lives of Radiometer associates and customers. Let me tell you a bit about why my work is so meaningful to me.”
Eduardo’s commitment to Radiometer goes beyond his professional responsibilities. A few years ago, he and his wife welcomed a beautiful baby girl into the world. However, soon after, they were faced with the challenging reality of their baby spending several weeks in the NICU due to premature birth. During this difficult time, Eduardo witnessed firsthand how Radiometer products played a crucial role in acute care diagnostics. Radiometer transcutaneous monitors provided vital information about his daughter’s oxygen levels and breathing patterns, offering his family much-needed peace of mind.
“This experience had a profound impact on me and made me realize the importance of the work that we do at Radiometer. In my role, I’m responsible for developing strategies that attract, hire, develop, and engage our fantastic associates. Building strong teams, seeing our team members grow, and partnering with different associates helps us achieve our goals and provide the best possible products and services to our customers and patients.”
Building Strong Teams and Supporting Growth
Eduardo’s role involves creating strategies that not only attract and hire top talent but also foster the growth and development of our associates. By building strong teams, Eduardo ensures that Radiometer continues to deliver exceptional products and services. His dedication to employee engagement and development is key to maintaining our high standards and achieving our mission.
“For me, my purpose working at Radiometer is more than just a job – it’s about giving patients and their families comfort and confidence that our products help healthcare professionals make the best medical decisions. I’m grateful for the opportunity to make a positive impact on people’s lives, and it’s what keeps me motivated to do my job every day.”
A Mission-Driven Career
Eduardo’s story is a powerful reminder of why Radiometer exists: to improve patient care through innovative healthcare solutions. His personal experience in the NICU reinforced the critical role that our products play in helping save lives and providing peace of mind to families during their most vulnerable moments.
Radiometer’s commitment to excellence is driven by leaders like Eduardo, who bring both professional expertise and personal passion to their roles. His journey highlights the profound impact that dedicated individuals can have within our organization and the broader healthcare community.
